Peringatan Keamanan

Since the drug was prepared from human plasma pool, it may contain other infectious agents such as viruses and Creutzfeldt-Jakob disease (vCJD) agent.
Hypersensitivity reactions such as allergic or anaphylactic reactions may occur. More common adverse effects include pain at injection site, headache, and rash. Rare adverse effects from immune globulin intravenous therapy include thrombotic events, renal dysfunction and acute renal failure, and noncardiogenic pulmonary edema. An LD50 was not determined, as the maximal dose used did not kill any experimental animals.

Human varicella-zoster immune globulin

DB11621

biotech approved

Deskripsi

Human varicella-zoster immune globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the disease severity in high-risk patients who lack evidence of immunity to varicella and for whom varicella vaccine is contraindicated. The therapeutic efficacy is proven if administered within 4 days of exposure to varicella zoster virus.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Human Varicella-Zoster Immunoglobulin has a half-life of about 18-24 days following intravenous administration and 24-30 days following intramuscular administration.
Volume Distribusi Following intravenous administration of varicella zoster VZIG, anti-varicella zoster antibodies are expected to be quickly distributed between plasma and extravascular spaces with complete and immediate bioavailability. Intramuscular administration achieves nearly 100% bioavailability.
Klirens (Clearance) -

Absorpsi

Intravenous administration of varicella zoster antibodies tends to persist for 6 weeks or longer. Following intramuscular administration of varicella immune globulin products, varicella antibodies are detectable within 2-3 days. The peak levels of varicella antibodies is expected to occur within 3-7 days of VariZIG administration.

Metabolisme

Immune globulins are metabolized in the reticuloendothelial system.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

372 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Estrone Estrone may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Estradiol Estradiol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Dienestrol Dienestrol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Mestranol Mestranol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Estriol Estriol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Quinestrol Quinestrol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Hexestrol Hexestrol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Tibolone Tibolone may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Zeranol Zeranol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Equol Equol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Promestriene Promestriene may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Methallenestril Methallenestril may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Epimestrol Epimestrol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Moxestrol Moxestrol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Biochanin A Biochanin A may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Formononetin Formononetin may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Estetrol Estetrol may increase the thrombogenic activities of Human varicella-zoster immune globulin.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Human varicella-zoster immune globulin.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Human varicella-zoster immune globulin.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Human varicella-zoster immune globulin.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Human varicella-zoster immune globulin.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Human varicella-zoster immune globulin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human varicella-zoster immune globulin.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Human varicella-zoster immune globulin.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Human varicella-zoster immune globulin.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Human varicella-zoster immune globulin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Human varicella-zoster immune globulin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Human varicella-zoster immune globulin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Human varicella-zoster immune globulin.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Human varicella-zoster immune globulin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human varicella-zoster immune globulin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Human varicella-zoster immune globulin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human varicella-zoster immune globulin.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Human varicella-zoster immune globulin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Human varicella-zoster immune globulin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human varicella-zoster immune globulin.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Human varicella-zoster immune globulin.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Human varicella-zoster immune globulin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Human varicella-zoster immune globulin.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human varicella-zoster immune globulin.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Human varicella-zoster immune globulin.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Human varicella-zoster immune globulin.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Human varicella-zoster immune globulin.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Human varicella-zoster immune globulin.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Human varicella-zoster immune globulin.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Human varicella-zoster immune globulin.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Human varicella-zoster immune globulin.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Human varicella-zoster immune globulin.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Human varicella-zoster immune globulin.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Human varicella-zoster immune globulin.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Human varicella-zoster immune globulin.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Human varicella-zoster immune globulin.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Human varicella-zoster immune globulin.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Human varicella-zoster immune globulin.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Human varicella-zoster immune globulin.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Human varicella-zoster immune globulin.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Human varicella-zoster immune globulin.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Human varicella-zoster immune globulin.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Human varicella-zoster immune globulin.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Human varicella-zoster immune globulin.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Human varicella-zoster immune globulin.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Human varicella-zoster immune globulin.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Human varicella-zoster immune globulin.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Human varicella-zoster immune globulin.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Human varicella-zoster immune globulin.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Human varicella-zoster immune globulin.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Human varicella-zoster immune globulin.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Human varicella-zoster immune globulin.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Human varicella-zoster immune globulin.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Human varicella-zoster immune globulin.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Human varicella-zoster immune globulin.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Human varicella-zoster immune globulin.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Human varicella-zoster immune globulin.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Human varicella-zoster immune globulin.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human varicella-zoster immune globulin.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Human varicella-zoster immune globulin.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Human varicella-zoster immune globulin.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Human varicella-zoster immune globulin.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Human varicella-zoster immune globulin.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Human varicella-zoster immune globulin.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Human varicella-zoster immune globulin.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Human varicella-zoster immune globulin.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Human varicella-zoster immune globulin.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Human varicella-zoster immune globulin.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Human varicella-zoster immune globulin.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Human varicella-zoster immune globulin.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Human varicella-zoster immune globulin.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 6341478
    Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, LeGore J: Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis. 1983 Apr;147(4):737-43.
  • PMID: 16188790
    Murguia-de-Sierra T, Villa-Guillen M, Villanueva-Garcia D, Molina A, Juarez-Chavez A, Leistikow EA: Varicella zoster virus antibody titers after intravenous zoster immune globulin in neonates, and the safety of this preparation. Acta Paediatr. 2005 Jun;94(6):790-3.
  • PMID: 23886000
    Andrei G, Snoeck R: Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107-68. doi: 10.1016/B978-0-12-405880-4.00004-4.
  • PMID: 6326634
    Authors unspecified: Varicella-zoster immune globulin for the prevention of chickenpox. Recommendations of the Immunization Practices Advisory Committee, Centers for Disease Control. Ann Intern Med. 1984 Jun;100(6):859-65.
  • PMID: 23863705
    Authors unspecified: Updated recommendations for use of VariZIG--United States, 2013. MMWR Morb Mortal Wkly Rep. 2013 Jul 19;62(28):574-6.
  • PMID: 19630862
    Fernandez-Cruz E, Alecsandru D, Sanchez Ramon S: Mechanisms of action of immune globulin. Clin Exp Immunol. 2009 Sep;157 Suppl 1:1-2. doi: 10.1111/j.1365-2249.2009.03955.x.
  • PMID: -
    Sewell WAC and Jolles S: Immunomodulatory action of intravenous immunoglobulin Immunology. 2002 December 1;107(4):387-393.

Contoh Produk & Brand

Produk: 9 • International brands: 0
Produk
  • Varicella Zoster Immune Globulin Inj
    Liquid • 125 unit / 2.5 mL • Intramuscular • Canada • Approved
  • Varicella-zoster Immune Globulin (human)
    Liquid • 100 unit / mL • Intramuscular • Canada • Approved
  • Varizig
    Kit • 125 [iU]/1mL • Intramuscular • US • Approved
  • Varizig
    Solution • 125 [iU]/1 • Intramuscular • US • Approved
  • Varizig
    Liquid • 1.25 [iU]/1mL • Intramuscular • US • Approved
  • Varizig
    Kit • 125 unit / vial • Intramuscular; Intravenous • Canada • Approved
  • Varizig
    Solution • 125 unit / vial • Intramuscular; Intravenous • Canada • Approved
  • Varizig
    Solution • 125 [iU]/1.2mL • Intramuscular • US • Approved
Menampilkan 8 dari 9 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul